 |
| CALL FOR SPEAKERS |
|
|
Inside This Issue: Parkinson's Disease
Top News Alerts: Product Updates, Deals & Financings
Featured Company: Zenobia pursues new target in Parkinson's
Subscribe now to access over 40 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Late State Obesity Drugs Deliver Results, Partnering on the Horizon?
Arena (ARNA), Orexigen (OREX) and Vivus (VVUS) all announced much anticipated trial results this month for their weight loss treatments in late stage development. None of the four compounds in development have secured a much needed marketing partner and it is expected that the latest data could trigger some action on the part of big pharma, which to date has been reticent to make a bet in the face of upcoming FDA scrutiny. Fears stemming from the Fen-phen debacle and the potential for widespread use and misuse of the drugs in the general population make obesity something of a pariah in the partnering world...
Parkinson's Disease: The Search for Disease Modifying Treatments
Parkinson's disease is the most common neurodegenerative condition in the Western World. It has been recognized since antiquity and was first described by Galen in 175 AD. The disease was named Parkinson's disease (PD) by French neurologist Jean-Martin Charcot after he read a publication entitled: "An Essay on the Shaking Palsy," by British physician James Parkinson, published in 1817. Although Parkinson's is an idiopathic disease that mostly affects elderly patients, aged 50 and over, there are rare instances of early onset Parkinsonism. One such case affecting the popular actor Michael J. Fox has raised awareness of this illness in the general population. Other well known figures suffering from PD include Muhammad Ali, and Olympic cyclist Davis Phinney. This month's feature article reviews the causes of Parkinson's disease, promising treatments in development and products on the market including drugs, devices and diagnostics...
Zenobia Therapeutics: A New Approach to Parkinson's
Zenobia Therapeutics was founded in June 2008 primarily to work on a Michael J. Fox Foundation funded Parkinson's disease project. Dr. Vicki Nienaber, President and CSO of the company said, "I had a personal interest in PD which runs in my family and expertise in kinases from my work in oncology. It was an ideal situation." To take advantage of the grant, the founders hooked up with a research group at Johns Hopkins, famous for its work on animal models of PD...
Companies Covered in this Issue include: 23andMe, Abiant Acadia Pharmaceuticals, Adamas, Addex Pharma, Alpine Biomed, Alexza, Amarin, Aspect Medical, Ardian, Arena, Axogen, Axxonis, BioLineRx, Biovail, Biogen Idec, BioVista, Bristol Myers-Squibb, Catalyst Pharmaceutical Partners, Cephalon, Cerimon, Ceregene, Chelsea Therapeutics, China Aoxing Pharmaceutical, Cochlear, CoLucid, Covidien, Dainippon, Decode Genetics, Domain Thera, Durect, Eli Lilly, Eisai, GSK, ImThera Medical, InSound, Kyowa, Medtronic, Merck Serono, Orexigen, Natus Medical, Neuralstem, Neurim, NeuroGeneration, NeuroHealing, NeuroMetrix, NeuroNova, NeuroPsychoTherapeutics, NeuroSearch, Newron, Novartis, Optherion, Santhera, Schwartz, Seaside Therapeutics, Shering AG, Shire, Solvay, Somerset, Solvay, St. Jude Medical, Supernus, Synosia, Titan, Valeant, Vernalis, Vitapath, UCB, Xenoport, Zenobia, Zogenix and more
Subscribe Now to Access this Issue and the Online Archive:
|
|
